Eculizumab Treatment: Uses, Side Effects, Dosing & Costs Explained

Summary of Key Points

Eculizumab is a prescription medication used to treat several rare and serious immune and blood-related conditions. It works by inhibiting a part of the immune system that can mistakenly attack healthy cells. Eculizumab is commonly prescribed for conditions such as atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and myasthenia gravis (MG). Always consult your healthcare provider before starting or adjusting this medication. You can also schedule a telemedicine appointment with one of our providers for personalized care.

Names of Medication

US Brand Name: Soliris

Generic Name: Eculizumab

The generic name refers to the active ingredient in the medication, while the brand name is the name under which the manufacturer markets the drug. In this case, Eculizumab is the generic name.

Pharmacologic Category

Complement Inhibitor

Eculizumab Dosing Guidelines

Eculizumab is used to treat various conditions, and the dosing schedule depends on the specific condition being managed. Always follow your doctor’s instructions carefully, and do not adjust your dose without consulting a healthcare provider. If you have any questions about your treatment plan, you can schedule a telemedicine appointment with one of our providers.

Eculizumab for Atypical Hemolytic Uremic Syndrome (aHUS)

Initial Dose: 900 mg intravenously (IV) weekly for 4 weeks

Maintenance Dose: 1200 mg IV at week 5, then every 2 weeks

Length of Treatment: Long-term treatment may be necessary

Eculizumab for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Initial Dose: 600 mg IV weekly for 4 weeks

Maintenance Dose: 900 mg IV at week 5, then every 2 weeks

Length of Treatment: Long-term treatment may be necessary

Eculizumab for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Initial Dose: 900 mg IV weekly for 4 weeks

Maintenance Dose: 1200 mg IV at week 5, then every 2 weeks

Length of Treatment: Long-term treatment may be necessary

Eculizumab for Myasthenia Gravis (MG)

Initial Dose: 900 mg IV weekly for 4 weeks

Maintenance Dose: 1200 mg IV at week 5, then every 2 weeks

Length of Treatment: Long-term treatment may be necessary

Eculizumab for Guillain-Barré Syndrome (GBS)

Initial Dose: 900 mg IV weekly for 4 weeks

Maintenance Dose: 1200 mg IV at week 5, then every 2 weeks

Length of Treatment: Long-term treatment may be necessary

Eculizumab for Hemolytic Uremic Syndrome (HUS)

Initial Dose: 900 mg IV weekly for 4 weeks

Maintenance Dose: 1200 mg IV at week 5, then every 2 weeks

Length of Treatment: Long-term treatment may be necessary

Eculizumab for Chronic Kidney Disease (CKD)

Initial Dose: 900 mg IV weekly for 4 weeks

Maintenance Dose: 1200 mg IV at week 5, then every 2 weeks

Length of Treatment: Long-term treatment may be necessary

Eculizumab for Thrombotic Thrombocytopenic Purpura (TTP)

Initial Dose: 900 mg IV weekly for 4 weeks

Maintenance Dose: 1200 mg IV at week 5, then every 2 weeks

Length of Treatment: Long-term treatment may be necessary

Eculizumab for Complement-Mediated Diseases

Initial Dose: 900 mg IV weekly for 4 weeks

Maintenance Dose: 1200 mg IV at week 5, then every 2 weeks

Length of Treatment: Long-term treatment may be necessary

Eculizumab for C3 Glomerulopathy

Initial Dose: 900 mg IV weekly for 4 weeks

Maintenance Dose: 1200 mg IV at week 5, then every 2 weeks

Length of Treatment: Long-term treatment may be necessary

Dosage Forms and Strengths

Injection, solution: 300 mg/30 mL (10 mg/mL)

Administration Instructions for Eculizumab Infusion Therapy

Eculizumab is administered as an intravenous (IV) infusion, meaning it is delivered directly into a vein by a healthcare professional. The infusion typically takes about 35 minutes. It is essential to follow your doctor’s instructions regarding the timing and frequency of your infusions. If you miss a dose, contact your healthcare provider immediately. If you have concerns about your treatment, you can schedule a telemedicine appointment with one of our providers to discuss your options.

Contraindications for Eculizumab Treatment

A contraindication is a specific situation or condition where a medication should not be used because it may be harmful. Several contraindications must be considered before starting Eculizumab treatment.

Active Meningococcal Infection: Eculizumab increases the risk of severe infections, particularly meningococcal infections. If you have an active meningococcal infection, taking Eculizumab could worsen the infection or make it more difficult to treat.

Not Vaccinated Against Meningococcal Disease: Patients who have not received a meningococcal vaccine should not take Eculizumab. This medication suppresses part of the immune system, increasing vulnerability to life-threatening infections. Vaccination is required at least two weeks before starting Eculizumab to reduce this risk.

Hypersensitivity to Eculizumab or Its Components: If you have had an allergic reaction to Eculizumab or any of its ingredients, you should not take this medication. Allergic reactions can range from mild to severe and may include symptoms such as rash, swelling, or difficulty breathing.

Drug to Drug Interactions

It is crucial to inform your healthcare provider about all medications you are currently taking, as Eculizumab can interact with other drugs. Some medications may increase the risk of side effects or reduce the effectiveness of Eculizumab. Below are some known drug interactions:

Immunosuppressants: Medications such as Azathioprine (Imuran) or Cyclophosphamide (Cytoxan) may heighten the risk of infections when taken alongside Eculizumab, as both suppress the immune system.

Live Vaccines: Vaccines like the Measles, Mumps, and Rubella (MMR) vaccine or the Varicella (chickenpox) vaccine should be avoided while on Eculizumab, as the medication can weaken your ability to fight infections from live vaccines.

Eculizumab in Pregnancy

Is it safe to take Eculizumab during pregnancy?

The safety of Eculizumab during pregnancy has not been fully established. Some studies suggest that Eculizumab may cross the placenta and potentially affect the baby, but the full extent of the risks remains unclear. If you are pregnant or planning to become pregnant, it is important to discuss the potential risks and benefits of Eculizumab treatment with your healthcare provider. They will help you weigh the risks of untreated disease against any potential risks to your baby. If you are already taking Eculizumab and become pregnant, do not stop the medication without first consulting your healthcare provider.

Eculizumab while Breastfeeding

Is it safe to take Eculizumab while breastfeeding?

There is limited information on whether Eculizumab passes into breast milk. However, because Eculizumab is a large protein molecule, it is unlikely to be absorbed in significant amounts by the infant. Nevertheless, the potential risks to the baby are not fully understood. If you are breastfeeding or plan to breastfeed, it is important to discuss this with your healthcare provider. They may recommend monitoring your infant for any signs of infection or other side effects.

Estimated Cost of Eculizumab

The cost of Eculizumab can be significant. Without insurance, the estimated cost of a 30-day supply of Eculizumab using a GoodRX coupon ranges from approximately $40,000 to $50,000. The exact cost may vary depending on the pharmacy and your location. If you are concerned about the cost of your medication, speak with your healthcare provider or a telemedicine provider to explore options for financial assistance or alternative treatments.

Possible Alternatives to Eculizumab

If Eculizumab is not suitable for you, there may be alternative treatments or lifestyle changes that can help manage your condition. Always discuss these alternatives with your healthcare provider before making any changes to your treatment plan. Below are some alternatives for the conditions Eculizumab is used to treat:

1. Atypical Hemolytic Uremic Syndrome (aHUS): Plasma exchange or plasma infusion may be used as an alternative to Eculizumab. In some cases, supportive care such as dialysis may be necessary.
2. Paroxysmal Nocturnal Hemoglobinuria (PNH): Bone marrow transplantation or other complement inhibitors like Ravulizumab (Ultomiris) may be considered as alternatives.
3. Neuromyelitis Optica Spectrum Disorder (NMOSD): Immunosuppressive therapies such as Rituximab (Rituxan) or Azathioprine (Imuran) may be used to manage symptoms.
4. Myasthenia Gravis: Medications such as Pyridostigmine (Mestinon) or immunosuppressants like Prednisone may be considered as alternatives.
5. Guillain-Barré Syndrome: Intravenous immunoglobulin (IVIG) or plasma exchange may be used to treat this condition.
6. Hemolytic Uremic Syndrome (HUS): Supportive care, including hydration and dialysis, may be used to manage symptoms.
7. Chronic Kidney Disease (CKD): Lifestyle changes such as a low-sodium diet, blood pressure management, and medications like ACE inhibitors or ARBs may help manage CKD.
8. Thrombotic Thrombocytopenic Purpura (TTP): Plasma exchange and immunosuppressive therapy are commonly used to treat TTP.
9. Complement-Mediated Diseases: Other complement inhibitors like Ravulizumab (Ultomiris) may be considered for certain complement-mediated diseases.
10. C3 Glomerulopathy: Immunosuppressive therapies or plasma exchange may be used as alternatives to Eculizumab.

Recent Updates on Eculizumab Research

Recent studies on Eculizumab continue to explore its effectiveness in treating various complement-mediated diseases. Ongoing research is investigating the long-term safety of Eculizumab, particularly in patients with rare conditions like Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS). Additionally, newer complement inhibitors such as Ravulizumab (Ultomiris) are being studied as alternatives to Eculizumab, offering the potential for less frequent dosing with similar efficacy. Researchers are also examining the use of Eculizumab in other autoimmune and inflammatory conditions, expanding its potential applications.

If you have questions about recent research or are interested in learning more about ongoing clinical trials, consider scheduling a telemedicine appointment with one of our healthcare providers. They can help you understand how these developments may impact your treatment plan.

James Kingsley

Learn More